Literature DB >> 18268523

Therapy Insight: gastrointestinal complications of diabetes--pathophysiology and management.

Joseph H Sellin1, Eugene B Chang.   

Abstract

Patients with diabetes often have gastrointestinal symptoms, but the extent and severity of this problem and the specificity of the symptoms are not nearly as well defined as frequently assumed. Any part of the gastrointestinal tract can be affected, and the presenting symptoms depend on the composite of dysfunctional elements. Gastroesophageal reflux, Candida esophagitis, gastroparesis, diarrhea and constipation are among the many common gastrointestinal complications of diabetes. No specific risk factor for the development of these complications has been identified and their etiology is most likely to be multifactorial, involving both reversible and irreversible processes. Treatment should be directed at tighter glycemic and symptom control, which can bring about clinical improvement for many patients. For other patients, however, effective clinical management is problematic because no therapies are available to prevent or correct the underlying disease mechanisms. Studies now suggest that reduced levels of key trophic factors cause transdifferentiation of pacemaker interstitial cells of Cajal into a smooth-muscle-like phenotype. If this really is the case, therapies directed at restoring the normal milieu of trophic signals could correct the dysfunction of the interstitial cells of Cajal and resolve many gastrointestinal complications. Advances in stem cell technology also hold promise to provide a cure for diabetes and to correct abnormalities in gastrointestinal pathology.

Entities:  

Mesh:

Year:  2008        PMID: 18268523     DOI: 10.1038/ncpgasthep1054

Source DB:  PubMed          Journal:  Nat Clin Pract Gastroenterol Hepatol        ISSN: 1743-4378


  17 in total

1.  Upper gastrointestinal motility and symptoms in individuals with diabetes, prediabetes and normal glucose tolerance.

Authors:  Georgios C Boronikolos; Björn A Menge; Nina Schenker; Thomas G K Breuer; Jan-Michel Otte; Sascha Heckermann; Freimut Schliess; Juris J Meier
Journal:  Diabetologia       Date:  2015-03-01       Impact factor: 10.122

Review 2.  Diabetes and the Esophagus.

Authors:  Roberto Monreal-Robles; José M Remes-Troche
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

3.  Fatty acid synthase modulates intestinal barrier function through palmitoylation of mucin 2.

Authors:  Xiaochao Wei; Zhen Yang; Federico E Rey; Vanessa K Ridaura; Nicholas O Davidson; Jeffrey I Gordon; Clay F Semenkovich
Journal:  Cell Host Microbe       Date:  2012-02-16       Impact factor: 21.023

Review 4.  The pathophysiology of chronic constipation.

Authors:  Christopher N Andrews; Martin Storr
Journal:  Can J Gastroenterol       Date:  2011-10       Impact factor: 3.522

5.  Treatment of patients with diabetic gastroparesis.

Authors:  Henry P Parkman; Ronnie Fass; Amy E Foxx-Orenstein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-06

6.  Diabetic diarrhea.

Authors:  Milena Gould; Joseph H Sellin
Journal:  Curr Gastroenterol Rep       Date:  2009-10

Review 7.  Diabetic gastrointestinal motility disorders and the role of enteric nervous system: current status and future directions.

Authors:  S S Yarandi; S Srinivasan
Journal:  Neurogastroenterol Motil       Date:  2014-03-24       Impact factor: 3.598

8.  Gastro-oesophageal reflux disease in type 2 diabetics: symptom load and pathophysiologic aspects - a retro-pro study.

Authors:  Regina Promberger; Johannes Lenglinger; Otto Riedl; Gernot Seebacher; Wolf Eilenberg; Johannes Ott; Franz Riegler; Michael Gadenstätter; Christoph Neumayer
Journal:  BMC Gastroenterol       Date:  2013-08-23       Impact factor: 3.067

9.  Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).

Authors:  Anne T Nies; Ute Hofmann; Claudia Resch; Elke Schaeffeler; Maria Rius; Matthias Schwab
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

10.  Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.

Authors:  William Phillips; Linda B Piller; Jeff D Williamson; Jeffrey Whittle; Syed Z A Jafri; Charles E Ford; Paula T Einhorn; Suzanne Oparil; Curt D Furberg; Richard H Grimm; Michael H Alderman; Barry R Davis; Jeffrey L Probstfield
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-08-07       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.